Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity. The study aims to evaluate the safety and tolerability of eloralintide alone and in combination with tirzepatide in overweight or obese individuals, focusing on how these drugs are absorbed and processed by the body.
Intervention/Treatment: The study tests two interventions: Eloralintide and a combination of Eloralintide with Tirzepatide. Both are administered subcutaneously and are designed to assess their safety and bioavailability in the body.
Study Design: This is an interventional study with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is basic science, focusing on understanding the drugs’ effects and safety profile.
Study Timeline: The study began on April 9, 2025, with the last update submitted on August 6, 2025. These dates are crucial as they indicate the study’s progress and current status, which is actively recruiting participants.
Market Implications: This study could significantly impact Eli Lilly’s stock performance and investor sentiment, especially if the results show positive safety and efficacy profiles. As the obesity treatment market is competitive, successful outcomes could enhance Eli Lilly’s position against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.